Dr. Suzanne Fanning, D.O

Hematology & Oncology Greenville, SC Female
NPI: 1568664480
Total Payments
$1.3M
2024 Payments
$108,824
Companies
41
Transactions
926
Medicare Patients
2,716
Medicare Billing
$358,051

Payment Breakdown by Category

Other$768,825 (59.4%)
Consulting$187,848 (14.5%)
Research$186,720 (14.4%)
Travel$133,845 (10.3%)
Food & Beverage$17,277 (1.3%)
Education$253.98 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $755,716 220 58.4%
Consulting Fee $187,848 89 14.5%
Unspecified $186,720 11 14.4%
Travel and Lodging $133,845 305 10.3%
Food and Beverage $17,277 286 1.3%
Honoraria $8,954 2 0.7%
Compensation for serving as faculty or as a speaker for a medical education program $3,405 2 0.3%
Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $750.00 1 0.1%
Education $253.98 10 0.0%

Payments by Type

General
$1.1M
915 transactions
Research
$186,720
11 transactions

Top Paying Companies

Company Total Records Latest Year
Celgene Corporation $525,885 316 $0 (2024)
Takeda Pharmaceuticals U.S.A., Inc. $331,216 213 $0 (2024)
E.R. Squibb & Sons, L.L.C. $113,146 74 $0 (2024)
Millennium Pharmaceuticals, Inc. $70,008 46 $0 (2017)
GENZYME CORPORATION $61,736 36 $0 (2024)
ADC Therapeutics America, Inc. $41,686 40 $0 (2024)
ABBVIE INC. $31,368 26 $0 (2024)
Genmab U.S., Inc. $27,301 56 $0 (2024)
Genentech, Inc. $12,225 9 $0 (2022)
AstraZeneca Pharmaceuticals LP $10,601 7 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $108,824 96 Takeda Pharmaceuticals U.S.A., Inc. ($29,843)
2023 $122,627 138 E.R. Squibb & Sons, L.L.C. ($53,497)
2022 $122,268 97 E.R. Squibb & Sons, L.L.C. ($32,163)
2021 $105,575 62 Takeda Pharmaceuticals U.S.A., Inc. ($31,249)
2020 $85,121 56 Celgene Corporation ($39,037)
2019 $210,059 173 Celgene Corporation ($117,035)
2018 $276,694 149 Celgene Corporation ($166,509)
2017 $263,600 155 Celgene Corporation ($192,619)

All Payment Transactions

926 individual payment records from CMS Open Payments — Page 1 of 38

Date Company Product Nature Form Amount Type
12/31/2024 ABBVIE INC. VENCLEXTA (Drug) Consulting Fee Cash or cash equivalent $2,900.00 General
Category: ONCOLOGY
12/31/2024 ABBVIE INC. ELAHERE (Drug) Food and Beverage In-kind items and services $34.30 General
Category: ONCOLOGY
12/24/2024 ABBVIE INC. EPKINLY (Drug) Consulting Fee Cash or cash equivalent $725.00 General
Category: ONCOLOGY
12/19/2024 GENZYME CORPORATION SARCLISA (Biological) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,909.00 General
Category: Oncology
12/12/2024 GENZYME CORPORATION SARCLISA (Biological) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,909.00 General
Category: Oncology
12/08/2024 GENZYME CORPORATION SARCLISA (Biological) Food and Beverage In-kind items and services $62.16 General
Category: Oncology
12/08/2024 Genmab U.S., Inc. — Food and Beverage In-kind items and services $61.86 General
12/08/2024 ADC Therapeutics America, Inc. — Food and Beverage In-kind items and services $48.92 General
12/08/2024 ABBVIE INC. EPKINLY (Drug) Food and Beverage In-kind items and services $34.27 General
Category: ONCOLOGY
12/07/2024 BeiGene USA, Inc. BRUKINSA (Drug) Food and Beverage In-kind items and services $120.01 General
Category: Oncology
12/06/2024 BeiGene USA, Inc. BRUKINSA (Drug) Consulting Fee Cash or cash equivalent $1,950.00 General
Category: Oncology
12/02/2024 E.R. Squibb & Sons, L.L.C. ABECMA (Biological) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,397.00 General
Category: Oncology
12/02/2024 Janssen Scientific Affairs, LLC DARZALEX (Biological) Consulting Fee Cash or cash equivalent $1,260.00 General
Category: Oncology
11/14/2024 ADC Therapeutics America, Inc. — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $4,960.00 General
11/14/2024 Genmab U.S., Inc. Epkinly (Drug) Consulting Fee Cash or cash equivalent $3,562.00 General
Category: Oncology
11/11/2024 ADC Therapeutics America, Inc. — Travel and Lodging Cash or cash equivalent $1,205.00 General
11/08/2024 ADC Therapeutics America, Inc. — Food and Beverage Cash or cash equivalent $119.29 General
11/06/2024 Incyte Corporation — Consulting Fee Cash or cash equivalent $2,397.50 General
11/06/2024 AstraZeneca Pharmaceuticals LP — Consulting Fee Cash or cash equivalent $1,230.00 General
10/30/2024 Takeda Pharmaceuticals U.S.A., Inc. ICLUSIG (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $8,800.00 General
Category: ONCOLOGY
10/30/2024 Takeda Pharmaceuticals U.S.A., Inc. ICLUSIG (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $6,160.00 General
Category: ONCOLOGY
10/26/2024 Genmab U.S., Inc. Epkinly (Drug) Travel and Lodging Cash or cash equivalent $134.00 General
Category: Oncology
10/26/2024 Genmab U.S., Inc. Epkinly (Drug) Travel and Lodging Cash or cash equivalent $64.00 General
Category: Oncology
10/26/2024 Genmab U.S., Inc. Epkinly (Drug) Food and Beverage In-kind items and services $31.46 General
Category: Oncology
10/26/2024 Genmab U.S., Inc. Epkinly (Drug) Food and Beverage In-kind items and services $22.48 General
Category: Oncology
123…38»

Research Studies & Clinical Trials

Study Name Company Amount Records
CC-5013-NHL-008 - A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicu Celgene Corporation $76,197 2
CC-5013-NHL-008 Celgene Corporation $68,033 2
The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT Takeda Pharmaceuticals U.S.A., Inc. $29,100 4
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) Celgene Corporation $12,265 2
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes HR MDS, Chronic Myelomonocytic Leukemia CMML and Low-Blast Acute Myelogenous Leukemia AML Takeda Pharmaceuticals U.S.A., Inc. $1,125 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 8 631 1,264 $195,167 $82,236
2022 8 631 1,417 $217,875 $90,444
2021 10 719 1,485 $239,107 $100,358
2020 7 735 1,608 $236,568 $85,014
Total Patients
2,716
Total Services
5,774
Medicare Billing
$358,051
Procedure Codes
33

All Medicare Procedures & Services

33 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 253 706 $111,619 $48,397 43.4%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2023 213 321 $33,088 $14,205 42.9%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2023 68 68 $17,658 $6,098 34.5%
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes Facility 2023 32 95 $14,155 $5,686 40.2%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2023 25 25 $5,501 $2,598 47.2%
99205 New patient office or other outpatient visit, 60-74 minutes Office 2023 16 16 $5,328 $2,182 40.9%
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes Facility 2023 12 21 $4,494 $1,891 42.1%
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes Facility 2023 12 12 $3,324 $1,180 35.5%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 274 722 $113,003 $49,505 43.8%
99232 Follow-up hospital inpatient care per day, typically 25 minutes Facility 2022 41 253 $37,697 $13,610 36.1%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2022 194 273 $27,564 $12,364 44.9%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2022 47 47 $12,126 $4,552 37.5%
99233 Follow-up hospital inpatient care per day, typically 35 minutes Facility 2022 23 58 $12,412 $4,495 36.2%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2022 20 24 $5,232 $2,378 45.4%
99222 Initial hospital inpatient care per day, typically 50 minutes Facility 2022 16 19 $5,263 $1,868 35.5%
99239 Hospital discharge day management, more than 30 minutes Facility 2022 16 21 $4,578 $1,671 36.5%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 307 821 $128,606 $57,528 44.7%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2021 54 205 $30,545 $10,998 36.0%
99213 Established patient outpatient visit, total time 20-29 minutes Office 2021 169 220 $22,176 $10,242 46.2%
99204 New patient outpatient visit, total time 45-59 minutes Office 2021 88 88 $22,761 $8,395 36.9%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 30 55 $11,770 $4,040 34.3%
36514 Mechanical separation of plasma from opening blood Facility 2021 14 30 $6,360 $2,201 34.6%
99222 Initial hospital inpatient care, typically 50 minutes per day Facility 2021 16 19 $5,263 $1,920 36.5%
99205 New patient outpatient visit, total time 60-74 minutes Office 2021 12 12 $3,996 $1,710 42.8%
99215 Established patient outpatient visit, total time 40-54 minutes Office 2021 13 15 $3,270 $1,699 51.9%
12»

About Dr. Suzanne Fanning, D.O

Dr. Suzanne Fanning, D.O is a Hematology & Oncology healthcare provider based in Greenville, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1568664480.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Suzanne Fanning, D.O has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $108,824 received in 2024. These payments were reported across 926 transactions from 41 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($755,716).

As a Medicare-enrolled provider, Fanning has provided services to 2,716 Medicare beneficiaries, totaling 5,774 services with total Medicare billing of $358,051. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.

Practice Information

  • Specialty Hematology & Oncology
  • Location Greenville, SC
  • Active Since 06/04/2007
  • Last Updated 08/02/2013
  • Taxonomy Code 207RH0003X
  • Entity Type Individual
  • NPI Number 1568664480

Products in Payments

  • Revlimid (Drug) $475,918
  • NINLARO (Drug) $294,684
  • Pomalyst (Drug) $83,765
  • SARCLISA (Biological) $61,644
  • ICLUSIG (Drug) $54,581
  • Epkinly (Drug) $27,194
  • EPKINLY (Drug) $25,644
  • ABECMA (Biological) $11,361
  • CALQUENCE (Drug) $7,535
  • IMBRUVICA (Drug) $6,476
  • UKONIQ (Drug) $5,175
  • VENCLEXTA (Drug) $5,150
  • BRUKINSA (Drug) $3,950
  • TECVAYLI (Biological) $2,992
  • XPOVIO (Drug) $2,931
  • BLENREP (Biological) $2,874
  • CARVYKTI (Drug) $2,539
  • ELZONRIS (Drug) $2,475
  • Rituxan (Drug) $2,320
  • ONUREG (Drug) $2,250

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Hematology & Oncology Doctors in Greenville

Dr. Joe Stephenson, Md, MD

Hematology & Oncology — Payments: $137,970

Hematology & Oncology $137,970

Dr. Paul Walker, M.d, M.D

Hematology & Oncology — Payments: $66,454

Hematology & Oncology $66,454

Dr. Darla Liles, Md, MD

Hematology & Oncology — Payments: $49,052

Hematology & Oncology $49,052

William Edenfield, Md, MD

Hematology & Oncology — Payments: $31,038

Hematology & Oncology $31,038

Dr. Raid Aljumaily, M.d, M.D

Hematology & Oncology — Payments: $21,498

Hematology & Oncology $21,498

Dr. Jay Walls, Md, MD

Hematology & Oncology — Payments: $13,590

Hematology & Oncology $13,590